Biomarker discovery study to identify patients with advanced urothelial cancer benefitting from pembrolizumab treatment

Trial Profile

Biomarker discovery study to identify patients with advanced urothelial cancer benefitting from pembrolizumab treatment

Recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Sep 2017

At a glance

  • Drugs Pembrolizumab (Primary)
  • Indications Urogenital cancer
  • Focus Biomarker; Pharmacodynamics
  • Acronyms RESPONDER
  • Most Recent Events

    • 03 Aug 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top